First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Onco360

    ONCS · 2 developments mapped · last assessed 2026-08-27

    Market Ontology has mapped 2 macro, policy, and market developments to Onco360 since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ONCS yet, so no modelled value is shown. The ONCS valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ONCS on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ONCS. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer

      Increased prescription volume and dispensing fees from being the national specialty dispensing partner for a newly approved oncology drug.

      · Moves revenue growth rate, profitability margins from new drug distribution

    What changed, by assumption

    Revenue growth rate
    • 2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
    Revenue growth rate from specialty pharmacy services
    • 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic CancerBullish1-3m0.60
    2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic CancerBullish1-3m0.60